Antiphospholipid antibodies and lipoprotein (a) as etiologic or contributory factors in patients with idiopathic cavernous transformation of portal vein

Turkish Journal of Gastroenterology

Volumn 13, Issue 2, 2002, Pages 89-93

  Egesel, Türker ^a   Ünsal, Ibrahim ^a   Bayraktar, Yusuf ^a  

^a NONE   (Turkey)

Author keywords

Antiphospholipid antibodies; Cavernous transformation of portal vein; Lipoprotein (a) anticardiolipin antibodies; Lupus anticoagulant

Indexed keywords

CARDIOLIPIN ANTIBODY; LIPOPROTEIN A; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC CAVERNOUS TRANSFORMATION OF PORTAL VEIN; MALE; PARAMETER; PORTAL VEIN THROMBOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOGENESIS; TURKEY (REPUBLIC); VEIN DISEASE;

EID: 0036314783     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Case of enlarged spleen complicated with ascites, both depending upon varicose dilatation and thrombosis of portal vein
2. The etiology, presentation and natural history of extrahepatic portal venous obstruction
3. Portal hypertension in myeloid metaplasia
4. Disease of the liver and biliary system
5. Hypercoagulability and thrombosis
6. Clinical and therapeutic aspects associated to phospholipid binding antibodies (lupus anticoagulant and anticardiolipin antibodies)
7. Plasma levels of lipoprotein (a) are elevated in patients with the antiphospholipid antibody syndrome
8. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary arterydisease documented by angiography
9. Lipoprotein (a) inhibits plasminogen activation in a template-dependent manner
10. Thrombocytopenia in SLE and related autoimmune disorders: Association with anticardiolipin antibody
11. Lupus anticoagulant
12. Lupus anticoagulant, recurrent abortion, and prostacyclin production by cultured smooth muscle cells
13. Developments in antiphospholipid-protein antibadies
14. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment
15. Autoantibodies to thrombomodulin: Development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant
16. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant
17. Protein S antibodies in acquired protein S deficiencies